Back to Results
First PageMeta Content
Medicine / Gilead Sciences / Fixed-dose combination / Hepatitis C virus / Interferon / Hepatitis C / Ribavirin / Food and Drug Administration / Antivirals / Pharmacology / Pharmaceutical sciences


Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C Press Release
Add to Reading List

Document Date: 2014-02-12 14:23:56

Open Document

File Size: 61,76 KB

Share Result on Facebook

City

CITY / FOSTER CITY / /

Company

Gilead Sciences Inc. / /

Continent

Europe / /

Country

United States / /

Event

FDA Phase / /

IndustryTerm

biopharmaceutical / investigational product / /

MedicalCondition

cirrhosis / hepatitis C / HCV / HCV Infection / compensated cirrhosis / infection / chronic hepatitis C / /

Organization

European Medicines Agency / U.S. Food and Drug Administration / European Commission / Committee for Medicinal Products for Human Use / European Union / U.S. Securities and Exchange Commission / /

Person

Norbert Bischofberger / /

Position

Executive Vice President of Research and Development and Chief Scientific Officer / Private / /

Product

Sovaldi / Ribavirin / ION-1 / Feb-2014 / Sofosbuvir Fixed-Dose Combination Tablet / combination / LDV/SOF / NS5A / Sovaldi® / /

ProvinceOrState

California / /

Region

South America / North America / Asia Pacific / /

Technology

Genotype / /

URL

www.Gilead.com / /

SocialTag